Is HDL function as important as HDL quantity in the coronary artery disease risk assessment?

Journal of Clinical Lipidology

Volumn 3, Issue 2, 2009, Pages 70-77

  Dodani, Sunita ^a   Grice, Deanna G ^b   Joshi, Sunil ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Coronary artery disease; Dyslipidemia; HDL; Inflammation; Oxidative stress

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE PHASE RESPONSE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 61949271495     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.02.001     Document Type: Review

References (44)

1. Okrainee K., Banerjee D.K., and Eisenberg M.J. Coronary artery disease in the developing world. Am Heart J 148 (2004) 7-15
2. Centers for Disease Control and Prevention. Heart Disease Death Rates, 2000-2004: Adults Age 35 Years and Older, By County. www.cdc.gov. c2008. Available at: http://www.cdc.gov/dhdsp/library/fs_heart_disease.htm.
3. Levy D., and Thom T.J. Death rates from coronary disease - progress and a puzzling paradox. N Engl J Med 339 (1998) 915-917
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
7. Kalhan R., Puthawala K., Agarwal S., Amini S.B., and Kalhan S.C. Altered lipid profile, leptin, insulin, and anthropometry in offspring of South Asian immigrants in the United States. Metabolism 50 (2001) 1197-1202
8. Curb J.D., Abbott R.D., Rodriguez B.L., et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: the Honolulu heart program. Am J Epidemiol 160 (2004) 150-157
9. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., and Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA (1986) 2835-2838
10. Tulenko T.N., and Sumner A.E. The physiology of lipoproteins. J Nucl Cardiol 9 (2002) 638-649
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
12. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
13. Ridker P.M., Danielson E., Fonseca F.A., et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
14. Brewer H.B. HDL metabolism and the role of HDL in the treatment of high risk patients with cardiovascular disease. Curr Cardiol Rep 9 (2007) 486-492
15. Cannon C.P. High density lipoprotien cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone 6 (2007) S14-23
16. Navab M., Yu R., and Gharavi N. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 9 (2007) 244-248
17. Libby P., and Plutzky J. Inflamation in diabetes mellitus. Am J Cardiol 99 suppl. (2007) 27B-40B
18. Watanbe J., Chou K.J., Liao J.C., et al. Differential association of hemoglobin with pro-inflammatory high density lipoproteins in atherogenic/hyperlipidemic mice-a novel biomarker of atherosclerosis. J Biochem 282 (2007) 23698-23707
19. Barter P.J., Nicholls S., and Rye K. Anti-inflammatory properties of HDL. Circ Res 95 (2004) 764-772
20. Radner M. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 116 (2006) 3090-3100
21. Navab M., Ananthramaiah G.M., and Reddy S.T. The double jeopardy of HDL. Ann Med 37 (2005) 173-178
22. Yancey P.G., Bortnick A.E., Kellner-Weibel G., et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thomb Vasc Biol (2003) 712-719
23. Ross R., and Glomset J.A. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 295 (1976) 369-377
24. Ross R., and Glomset J.A. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 295 (1976) 420-425
25. Rotllan N., Ribas V., and Calpe-Berdiel L. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 25 (2005) e128-e132
26. Movva R., and Rader D.J. Laboratory assessment of HDL heterogeneity and function. Clin Chem 54 (2008) 788-800
27. Von Eckardstein A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21 (2001) 13-27
28. Norato G.D., Pirillo A., and Catapano A.L. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 16 (2006) 371-386
29. Kontush A., and Chapman M.J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 3 (2006) 144-153
30. van der Steeg W.A., Holme I., Boekholdt S.M., et al. High density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol 51 (2008) 634-642
31. Sviridov D., Mukhamedova N., Remaley A.T., Chin-Dusting J., and Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15 (2008) 52-62
32. Ansell B.J., Fonarow G.C., and Fogelman A.M. High-density lipoprotein: is it always atheroprotective?. Curr Atheroscler Rep 8 (2006) 405-411
33. Fogelman A.M. When good cholesterol goes bad. Nat Med 10 (2004) 902-903
34. Dodani S., Kaur R., Mohammad N., et al. Can dysfunctional HDL explain excess risk of coronary artery diseases in south Asian immigrants?. Int J Cardiol 129 (2008) 125-132
35. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004) 529-541
36. Navab M., Anantharamaiah G.M., Reddy S.T., et al. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 15 (2004) 645-649
37. Shao B., Oda M.N., Oram J.F., and Heinecke J.W. Myeloperoxidase an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21 (2006) 322-328
38. Navab M., Hama Y., Hough G.P., Subbanagounder G., Reddy S.T., and Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42 (2001) 1308-1317
39. Ansell B.J., Navab N., and Hama S. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
40. Ansell B.J., Fonarow G.C., Navab M., and Fogelman A.M. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep 9 (2007) 57-63
41. Chan D.C., Barrett P.H., and Watts G.F. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Clin Sci (Lond) 107 (2004) 233-249
42. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 2 (2007) 257-260
43. Tall A.R. CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356 (2007) 1364-1366
44. Brown B.G., and Zhao X.Q. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 101 8A (2008) 58B-62B